Lei Yan, PhD
Associate Research Scientist in BiostatisticsDownloadHi-Res Photo
Cards
Contact Info
About
Copy Link
Titles
Associate Research Scientist in Biostatistics
Biography
I am an Associate Research Scientist in Biostatistics at Yale Public Health.
My research focuses on the application of advanced causal inference methods to questions in comparative effectiveness research, utilizing large electronic health records and other observational data to enhance health decision-making. Ongoing projects include estimating the causal effects of pharmacotherapies on the short- and long-term risk of COVID-19, examining the use of antidepressants and their effects on individuals with major depression, evaluating the effectiveness of respiratory syncytial virus vaccines, assessing the efficacy and duration of dolutegravir-based regimens for individuals with HIV, and investigating gene-environment interactions in the development of childhood acute lymphoblastic leukemia. These projects are conducted collaboratively with faculty and researchers at Yale Public Health and the Clinical Epidemiology Research Center (CERC) at the VA Connecticut Healthcare System located in West Haven. My previous research focused on the financialization of commodity markets.
Last Updated on January 20, 2024.
Appointments
Biostatistics
Associate Research ScientistPrimary
Other Departments & Organizations
Education & Training
- Postdoctoral Research Associate
- University of Illinois at Urbana-Champaign (2018)
- PhD
- University of Illinois at Urbana-Champaign, Applied Economics (2017)
- MA
- Renmin University of China, Economics (2011)
- BS
- Renmin University of China, Statistics (2008)
Research
Copy Link
Overview
Medical Research Interests
Data Science
Public Health Interests
Epidemiology Methods; HIV/AIDS; Survival Analysis; Pharmacoepidemiology
Publications
Featured Publications
Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study
Bajema K, Yan L, Li Y, Argraves S, Rajeevan N, Fox A, Vergun R, Berry K, Bui D, Huang Y, Lin H, Hynes D, Lucero-Obusan C, Schirmer P, Cunningham F, Huang G, Aslan M, Ioannou G. Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study. The Lancet Infectious Diseases 2025, 25: 625-633. PMID: 39848264, DOI: 10.1016/s1473-3099(24)00796-5.Peer-Reviewed Original ResearchCitationsAltmetricSeverity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus
Bajema K, Bui D, Yan L, Li Y, Rajeevan N, Vergun R, Berry K, Huang Y, Lin H, Aslan M, Ioannou G. Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus. JAMA Internal Medicine 2025, 185: 324-334. PMID: 39869355, PMCID: PMC11773409, DOI: 10.1001/jamainternmed.2024.7452.Peer-Reviewed Original ResearchCitationsAltmetricEffectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS)
Yan L, Henegar C, Marconi V, Gordon K, Hicks C, Vannappagari V, Justice A, Aslan M. Effectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS). AIDS Research And Therapy 2024, 21: 96. PMID: 39709467, PMCID: PMC11662819, DOI: 10.1186/s12981-024-00681-w.Peer-Reviewed Original ResearchCitationsAltmetricMeSH KeywordsAgedAmidesAnti-HIV AgentsCohort StudiesDarunavirDrug Therapy, CombinationFemaleHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsHIV InfectionsHIV Integrase InhibitorsHumansMaleMiddle AgedOxazinesPiperazinesPyridazinesPyridonesQuinolonesRaltegravir PotassiumTreatment OutcomeVeteransViral LoadIdentifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation
Yan L, Bui D, Li Y, Rajeevan N, Rowneki M, Berry K, Argraves S, Huang Y, Hynes D, Cunningham F, Huang G, Aslan M, Ioannou G, Bajema K. Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation. Clinical Infectious Diseases 2024, 79: 643-651. PMID: 38864601, DOI: 10.1093/cid/ciae202.Peer-Reviewed Original ResearchCitationsAltmetricImpact of time zero designation on estimated COVID-19 antiviral effectiveness in observational studies
Bajema K, Yan L, Berry K, Bui D, Lin H, Huang Y, Li Y, Rajeevan N, Maciejewski M, Smith V, Bohnert A, Hynes D, Aslan M, Ioannou G. Impact of time zero designation on estimated COVID-19 antiviral effectiveness in observational studies. American Journal Of Epidemiology 2025, 195: 562-568. PMID: 41078178, DOI: 10.1093/aje/kwaf221.Peer-Reviewed Original ResearchCitationsAltmetric
2026
Durability of Respiratory Syncytial Virus Vaccine Effectiveness Among US Veterans
Bajema K, Bui D, Yan L, Li Y, Rajeevan N, Vergun R, Sriskantharajah V, Hynes D, Berry K, Huang Y, Lin H, Aslan M, Ioannou G. Durability of Respiratory Syncytial Virus Vaccine Effectiveness Among US Veterans. JAMA Internal Medicine 2026, 186: 78-88. PMID: 41284307, PMCID: PMC12645397, DOI: 10.1001/jamainternmed.2025.6355.Peer-Reviewed Original ResearchCitationsAltmetric
2025
Effectiveness of the 2024–2025 KP.2 COVID-19 vaccines in the United States during long-term follow-up
Ioannou G, Berry K, Yan L, Huang Y, Lin H, Bui D, Hynes D, Boyko E, Ferguson J, Aslan M, Bajema K. Effectiveness of the 2024–2025 KP.2 COVID-19 vaccines in the United States during long-term follow-up. Nature Communications 2025, 17: 1043. PMID: 41444246, PMCID: PMC12847879, DOI: 10.1038/s41467-025-67796-0.Peer-Reviewed Original ResearchCitationsAltmetricLow-Altitude Sensing Standards: Institutional Support for Intelligence and Security
Yan L, Wu Y, Yan Z, Tat E, Lu H, Koo V, Hu S, Toh C, Shen T, Tensy K, Chen N, Chang Y, Wang L. Low-Altitude Sensing Standards: Institutional Support for Intelligence and Security. 2025, 00: 180-185. DOI: 10.1109/amict65811.2025.11402799.Peer-Reviewed Original ResearchComparative efficacy and safety of exercise modalities in knee osteoarthritis: systematic review and network meta-analysis
Yan L, Li D, Xing D, Fan Z, Du G, Jiu J, Li X, Estill J, Wang Q, Belal A, Tian C, Li J, Li S, Liu H, Liu X, Ren Y, Yang Y, Chen J, Hu Y, Ge L, Wang B. Comparative efficacy and safety of exercise modalities in knee osteoarthritis: systematic review and network meta-analysis. The BMJ 2025, 391: e085242. PMID: 41093618, PMCID: PMC12522397, DOI: 10.1136/bmj-2025-085242.Peer-Reviewed Original ResearchCitationsAltmetricBudget Impact of Adopting Nirmatrelvir-Ritonavir for Treating COVID-19 in a Large Integrated Healthcare System
Bui D, Hynes D, Wong E, Vergun R, Yan L, Li Y, Rajeevan N, Berry K, Lin H, Huang Y, Govier D, Aslan M, Ioannou G, Bajema K. Budget Impact of Adopting Nirmatrelvir-Ritonavir for Treating COVID-19 in a Large Integrated Healthcare System. Open Forum Infectious Diseases 2025, 12: ofaf596. PMID: 41089767, PMCID: PMC12517272, DOI: 10.1093/ofid/ofaf596.Peer-Reviewed Original ResearchAltmetric
Academic Achievements & Community Involvement
Copy Link
Activities
activity Scientific Reports
2024 - PresentJournal ServiceEditorial Board Memberactivity Polypharmacy, Drug-Drug Interactions, and Risk of Hospitalization among Veterans with HIV Taking 2-, 3-, and 4-Drug Antiretroviral Therapy Regimens
10/19/2025 - 10/22/2025Poster PresentationIDWeek 2025DetailsWashington, DC, United StatesCollaboratorsAbstract/Synopsishttps://academic.oup.com/ofid/article/13/Supplement_1/ofaf695.447/8420596
activity Using Target Trial Emulation and Decision Tree Analyses to Assess Budget Impact and Cost Effectiveness of Nirmatrelvir-Ritonavir (NR) Allocation Strategies
06/07/2025 - 06/10/2025Poster Presentation2025 Annual Research MeetingDetailsMinneapolis, MN, United StatesCollaboratorsAbstract/Synopsishttps://academyhealth.confex.com/academyhealth/2025arm/meetingapp.cgi/Paper/70571
activity Frequency of Overlapping Prescriptions With Known Pairwise Drug Interactions Among People With HIV Taking 2-, 3- And 4-Drug Regimens in the Veterans Aging Cohort Study
10/24/2024 - 10/25/2024Oral PresentationThe 15th International Workshop on Aging & HIVDetailsWashington, DC, United StatesCollaboratorsAbstract/Synopsishttps://academicmedicaleducation.com/materials/oral-abstract-19--frequency-of-overlapping-prescriptions-with-known-pairwise-drug-interactions-among-people-with-hiv-taking-2-3-and-4-drug-regimens-in-the-veterans-aging-cohort-study--lei-yan.pdf-18851
activity Effectiveness and durability of dolutegravir/lamivudine in older people with HIV from the Veterans Aging Cohort Study (VACS)
07/22/2024 - 07/26/2024Poster PresentationThe 25th International AIDS ConferenceDetailsMunich, BY, GermanyCollaborators
News
Copy Link
Get In Touch
Copy Link
Contacts
Email
Locations
300 George Street
Academic Office
Rm 509
New Haven, CT 06511